Kancera announces that the FRACTAL top line results are expected to be presented by the end of December 2023
Kancera provides operational update in connection with release of financial interim report for second quarter
Kancera reports promising preclinical results from studies of its Fractalkine axis blocking drug candidates in B-cell lymphoma
Kancera provides an update on the development of the company’s pharmaceutical project and nominates a new drug candidate
